Efficacy and safety of liposomal amphotericin B for the treatment of mucosal leishmaniasis from the new world: A retrospective study

American Journal of Tropical Medicine and Hygiene

Volumn 93, Issue 6, 2015, Pages 1214-1218

  Cunha, Mirella A ^a   Leão, Aline C Q ^a   De Cassia Soler, Rita ^a   Lindoso, José Angelo L ^a,b  

^a INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; AZITHROMYCIN; ITRACONAZOLE; PENTAMIDINE ISETHIONATE; PENTOXIFYLLINE; AMPHOTERICIN B; ANTIPROTOZOAL AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FEMALE; FEVER; HEART DISEASE; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY FAILURE; LEISHMANIASIS; LEISHMANIN SKIN TEST; MALE; MEDICAL HISTORY; MEDICAL RECORD REVIEW; MUCOSAL LEISHMANIASIS; MYALGIA; NOSE OBSTRUCTION; TREATMENT RESPONSE; VERY ELDERLY; BRAZIL; CHEMICALLY INDUCED; DRUG EFFECTS; LEISHMANIA; LEISHMANIASIS, MUCOCUTANEOUS; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; BRAZIL; FEMALE; HUMANS; LEISHMANIA; LEISHMANIASIS, MUCOCUTANEOUS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84949658956     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.15-0033     Document Type: Article

References (26)

1. Goto H, Lindoso JAL, 2010. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther 8:419-433.
2. Mitropoulos P, Konidas P, Durkin-Konidas M, 2010. New World cutaneous leishmaniasis: updated review of current and future diagnosis and treatment. J Am Acad Dermatol 63:309-322.
3. Amato VS, Tuon FF, Camargo RA, Souza RM, Santos CR, Nicodemo AC, 2011. Can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis? Am J Trop Med Hyg 85:818-819.
4. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S, 2007. Cutaneous leishmaniasis. Lancet Infect Dis 7:581-596.
5. Amato VS, Tuon FF, Bacha HA, Neto VA, Nicodemo AC, 2008. Mucosal leishmaniasis: current scenario and prospects for treatment. Acta Trop 105:1-9.
6. Strazzulla A, Cocuzza S, Pinzone MR, Postorino MC, Cosentino S, Serra A, Cacopardo B, Nunnari G, 2013. Mucosal leishmaniasis: an underestimated presentation of a neglected disease. Bio Med Res Int 2013:805108.
7. Ministério da Saúde do Brasil, 2007. Manual de Vigilância da Leishmaniose Tegumentar Americana. Available at: http://bvsms.saude.gov. br/bvs/publicacoes/manual-vigilancia-leishmaniose-2ed.pdf. Accessed October 16, 2014.
8. Guerra JA, Prestes SR, Silveira H, Coelho LI, Gama P, Moura A, Amato V, Barbosa MD, Ferreira LC, 2011. Mucosal leishmaniasis caused by Leishmania (Viannia) braziliensis and Leishmania (Viannia) guyanensis in the Brazilian Amazon. PLoS Negl Trop Dis 5:e980.
9. Amato VS, Tuon FF, Imamura R, Abegão de Camargo R, Duarte MI, Neto VA, 2009. Mucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil. J Eur Acad Dermatol Venereol 23:1026-1034.
10. Amato VS, Tuon FF, Siqueira AM, Nicodemo AC, Neto VA, 2007. Treatment of Mucosal leishmaniasis in Latin America: systematic review. Am J Trop Med Hyg 77:266-274.
11. Goto H, Lindoso JAL, 2012. Cutaneous and mucocutaneous leishmaniasis. Infect Dis Clin North Am 26:293-307.
12. McGwire BS, Satoskar AR, 2014. Leishmaniasis: clinical syndromes and treatment. QJM 107:7-14.
13. ™. Trans R Soc Trop Med Hyg 91:77.
14. Amato VS, Tuon FF, Campos A, Bacha HA, Nicodemo AC, Amato Neto V, Shikanai-Yasuda MA, 2007. Treatment of mucosal leishmaniasis with a lipid formulation of amphotericin B. Clin Infect Dis 44:311-312.
15. World Health Organization, 2010. Control of the Leishmaniases. Available at: http://whqlibdoc.who.int/trs/WHO-TRS-949-eng.pdf. Accessed October 16, 2014.
16. Sampaio RN, Marsden PD, 1997. Treatment of the mucosal form of leishmaniasis without response to glucantime, with liposomal amphotericin B. Rev Soc Bras Med Trop 30:125-128.
17. Andrade RV, Massone C, Lucena MN, Talhari AC, Talhari S, Guerra JA, Ferreira LC, 2011. The use of polymerase chain reaction to confirm diagnosis in skin biopsies consistent with American tegumentary leishmaniasis at histopathology: a study of 90 cases. An Bras Dermatol 86:892-896.
18. Schönian G, Nasereddin A, Dinse N, Schweynoch C, Schallig HD, Presber W, Jaffe CL, 2003. PCR diagnosis and characterization of Leishmania in local and imported clinical samples. Diagn Microbiol Infect Dis 47:349-358.
19. da Silva LA, de Sousa Cdos S, da Graça GC, Porrozzi R, Cupolillo E, 2010. Sequence analysis and PCR-RFLP profiling of the hsp70 gene as a valuable tool for identifying Leishmania species associated with human leishmaniasis in Brazil. Infect Genet Evol 10:77-83.
20. Motta JO, Sampaio RN, 2012. A pilot study comparing low-dose liposomal amphotericin B with N-methyl glucamine for the treatment of American cutaneous leishmaniasis. J Eur Acad Dermatol Venereol 26:331-335.
21. Monge-Maillo B, López-Vélez R, 2013. Therapeutic options for Old World cutaneous leishmaniasis and New World cutaneous and mucocutaneous leishmaniasis. Drugs 73:1889-1920.
22. Satow MM, Yamashiro-Kanashiro EH, Rocha MC, Oyafuso LK, Soler RC, Cotrim PC, Lindoso JA, 2013. Applicability of kDNA-PCR for routine diagnosis of American tegumentary leishmaniasis in a tertiary reference hospital. Rev Inst Med Trop Sao Paulo 55:393-399.
23. Franke ED, Wignall FS, Cruz ME, Rosales E, Tovar AA, Lucas CM, Llanos-Cuentas A, Berman JD, 1990. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Ann Intern Med 113:934-940.
24. Marsden PD, 1986. Mucosal leishmaniasis ("espundia" Escomel, 1911). Trans R Soc Trop Med Hyg 80:859-876.
25. Organización Panamericana de la Salud, 2013. Leishmaniasis en las Américas: recomendaciones para el tratamiento. Available at: http://www.paho.org/hq/index.php?option=com-docman&task= doc-view&gid=22226&Itemid. Accessed October 16, 2014.
26. Hamill RJ, 2013. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs 73:919-934.